The Effect of Ozone Therapy on Pain Perception After Free Gingival Graft Surgery in Patients With Mucogingival Defects

NCT ID: NCT05291715

Last Updated: 2023-02-14

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

20 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-06-15

Study Completion Date

2022-12-25

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Gaseous ozone (O3-triatomic oxygen) is the third-strongest oxidizing agent worldwide. It influences the cellular and the humoral immune system, by stimulating the proliferation of immunocompetent cells and the synthesis of immunoglobulin. Additionally; biologically active substances, such as interleukins, leukotrienes and prostaglandins which are beneficial in reducing inflammation and wound healing are orchestrated following ozone application. Given that after harvesting of a free gingival graft from the palatal donor site, healing occurs by secondary intention process; for patients with mucogingival conditions. The investigators will compare the natural process of healing at the donor site versus the healing process consecutive to ozone application; with the primary outcome is to evaluate the postoperative pain perception using visual analogue scale and to estimate the consumption of analgesics tablets after surgery.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The procedures will be explained to all participants and they will be asked to sign an informed consent.

All patients will receive oral hygiene instructions and will receive phase I therapy comprising supragingival scaling and subgingival debridement.

After completion of phase I therapy the patients will be re-examined to ensure meeting all inclusion criteria. Then the participants will be allocated to 2 groups.

Group I will receive ozone therapy after harvesting free gingival graft. Group II following the harvesting of the free gingival graft, will be protected by a periodontal pack.

Surgical intervention:

Graft harvesting at donor site (Sullivan, \& Atkins, 1968) To prepare the donor area, a rectangular-shape incision with 1-1.5 mm thickness will be made, and care will be taken to place most of the coronal part of the incision at least 2 mm apical from gingival margins of the upper teeth. The apical coronal dimension of the graft.

Following administration of anaesthesia by local infiltration (2% lidocaine with 1:100,000 epinephrine), a template will be placed over the palatal mucosa and will be used to outline the dimensions of the graft. The area chosen to harvest the free gingival graft will be chosen between first premolar and first molar.

The outlined graft will be carefully harvested as follows: The surgical blade entered in the contour incision, always in the posterior limit, sliding below the mucosa, and continued to find the opposite contour incision, in the anterior limit. The connective tissue surface will be carefully inspected for irregularities or adipose tissue after graft separation. Graft thickness will be immediately prepared (thinned) to obtain a graft approximately 1 to 1.5 mm thick.

The palatal wound will be protected by a periodontal pack; for the control group.

While the test group, will receive ozone therapy.

Ozone Application Protocol:

An ozone generator device (Ozone DTA-APOZAa- enterPrize Co9-Taiwan,R.0,C) with different probe numbers (#1 pointed probe,#2 pointed probe and #3 flat probe) will be used according to the manufacturer's instructions. Ozone will be applied on donor sites immediately after surgery and at days 1, 3, 7, 14 post-surgeries in the test group with output power at level 6-12 for 1 minute.

Ozone application in the control group will be simulated without starting the ozone generator.

Postoperative Protocol:

The participants will be instructed to abstain from brushing and flossing the teeth at the surgical area until suture removal (7days) and to use an antimicrobial rinse (0.12% chlorhexidine, 15 ml for 60 seconds twice daily) solution two times a day for 4 weeks.

The participants will be also instructed to consume only soft foods during the first week and to avoid any other mechanical trauma to the treated sites.

The participants will be given a prescription of Ibuprofen (600 mg every 12 hours) to be taken if necessary and the participants will be asked to record the number of tablets taken.

Participants will be enrolled in a professional plaque control program weekly for the first 4 weeks, then monthly until the end of the study.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Open Wound of Palate Without Complication Pain, Postoperative Free Gingival Grafts Mucogingival Defects Gingival Recession Donor Site Patient Satisfaction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Group 1: Will receive ozone therapy after harvesting a free gingival graft. Group 2: Following the harvesting of the free gingival graft; the palatal donor site will be protected by a periodontal pack.
Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Participants Outcome Assessors
Double- blinded

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

group 1, test group

This group will receive ozone therapy after harvesting of the free gingival graft from the palatal donor site.

Group Type EXPERIMENTAL

Ozone generator device (Ozone DTA-APOZAa-enterprize CO9-Taiwan, R.0.C)

Intervention Type DEVICE

Gaseous ozone ( O3-triatomic oxygen) activates the neuroprotective systems, improve the blood circulation, oxygen delivery, stimulate the immunocompetent cells and enhance the release of growth factors. Moreover, ozone therapy showed to increase the quality of life post-operatively to a free gingival graft harvesting and decrease post-operative pain sensation ( Tasdemir et al, 2016)

group 2, control group

Following harvesting of the free gingival graft, the palatal donor site ozone application will be simulated without starting of the ozone generator and the covered ( protected) by a periodontal pack.

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Ozone generator device (Ozone DTA-APOZAa-enterprize CO9-Taiwan, R.0.C)

Gaseous ozone ( O3-triatomic oxygen) activates the neuroprotective systems, improve the blood circulation, oxygen delivery, stimulate the immunocompetent cells and enhance the release of growth factors. Moreover, ozone therapy showed to increase the quality of life post-operatively to a free gingival graft harvesting and decrease post-operative pain sensation ( Tasdemir et al, 2016)

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with mucogingival defects to be treated with free gingival grafts.
* Age older than 18 years old.
* No history of periodontal surgery in the area to be treated.
* Full mouth plaque score (FMPS) and full mouth bleeding score (FMBS) less than 20%.

Exclusion Criteria

* Smoking
* Pregnancy and lactation.
* History of systematic diseases or medications that interferes with periodontal wound healing.
Minimum Eligible Age

18 Years

Maximum Eligible Age

50 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Omaima Mossad Mahmoud AL-Sherbini

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Omaima Mossad Mahmoud AL-Sherbini

Principle investigator

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Manal Hosny, Professor

Role: STUDY_DIRECTOR

Professor of Oral Diagnosis,Oral Medicine and Periodontology Faculty of Dentistry,Cairo University.

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Cairo University-Faculty of Dentistry

Cairo, Manial, Giza, Egypt

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Egypt

References

Explore related publications, articles, or registry entries linked to this study.

Miller PD Jr. Root coverage using the free soft tissue autograft following citric acid application. III. A successful and predictable procedure in areas of deep-wide recession. Int J Periodontics Restorative Dent. 1985;5(2):14-37. No abstract available.

Reference Type BACKGROUND
PMID: 3858263 (View on PubMed)

Ozcan M, Ucak O, Alkaya B, Keceli S, Seydaoglu G, Haytac MC. Effects of Platelet-Rich Fibrin on Palatal Wound Healing After Free Gingival Graft Harvesting: A Comparative Randomized Controlled Clinical Trial. Int J Periodontics Restorative Dent. 2017 Sep/Oct;37(5):e270-e278. doi: 10.11607/prd.3226.

Reference Type BACKGROUND
PMID: 28817141 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

131221

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Effect of I-PRF After Gingivectomy
NCT07174934 NOT_YET_RECRUITING NA